A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome.
Latest Information Update: 12 Apr 2022
At a glance
- Drugs AVE 0657 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Sanofi
- 08 Apr 2022 This trial has been completed in Spain (End Date: 30 March 2009) according to European Clinical Trials Database record.
- 01 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 29 Nov 2011 Status changed from recruiting to discontinued, according to ClinicalTrials.gov.